4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Osteosarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 274 ongoing clinical trials involving Osteosarcoma
Of the 274 trials,109 trials are in Phase II
Furthermore, 78 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Osteosarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Osteosarcoma, an oncology condition. The largest number of ongoing clinical trials for Osteosarcoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Osteosarcoma-related drug trials.

National Cancer Institute US: The leading ongoing Osteosarcoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Osteosarcoma-related ongoing clinical trials.

Children's Oncology Group, Peking University People's Hospital, Memorial Sloan Kettering Cancer Center, and University of Texas MD Anderson Cancer Center are among other notable clinical trial sponsors involved in Osteosarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Osteosarcoma

Carboplatin (Paraplatin, Carboplat, Paraplatine), and Pegylated liposomal doxorubicin (Doxil, Caelyx) are among the key marketed drugs involving Osteosarcoma.

Carboplatin (Paraplatin, Carboplat, Paraplatine), is an antineoplastic agent and chemotherapeutic agent, formulated as injection for intravenous use. It functions via DNA Synthesis Inhibitor mechanism of action. Carboplatin is indicated for palliative treatment (to ease symptoms rather than provide a cure) in patients with intial/recurred ovarian cancer, small cell lung cancer, head and neck squamous cell carcinoma. in combination with other drugs. Carboplatin was first approved in 1986 and is marketed globally including the US, France, Germany, China, and Japan by several pharma giants including Bristol-Myers Squibb Co, and Corden Pharma Switzerland LLC.

Pegylated liposomal doxorubicin (Doxil, Caelyx) is an anthracycline topoisomerase inhibitor isolated from Streptomyces peucetius var. caesius. It functions via DNA Synthesis Inhibitor; DNA Topoisomerase II (EC 5.99.1.3) Inhibitor mechanism of action. Doxil is encapsulated in the Stealth liposomes and follows lipid nanoparticle (LNP) drug delivery system. It is formulated as concentrate suspension pegylated liposomal injection for intravenous infusion administration. Pegylated liposomal doxorubicin was first approved in 1995 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several pharma giants including Johnson & Johnson.